Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

185.04B

Market cap185.04B

Price-Earnings ratio

23.91

Price-Earnings ratio23.91

Dividend yield

2.84%

Dividend yield2.84%

Average volume

2.31M

Average volume2.31M

High today

$346.00

High today$346.00

Low today

$342.80

Low today$342.80

Open price

$344.50

Open price$344.50

Volume

199.24K

Volume199.24K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $342.86. The company's market cap stands at 185.04B, with a P/E ratio of 23.91 and a dividend yield of 2.8%.

On 2026-04-28, Amgen(AMGN) stock moved within a range of $342.80 to $346.00. With shares now at $342.86, the stock is trading +0.0% above its intraday low and -0.9% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 199.24K, versus its average volume of 2.31M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

Seeking Alpha 33m

Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

The U.S. FDA has proposed to withdraw the marketing of Tavneos, a treatment developed by Amgen (AMGN) for a group of rare disorders called anti-neutrophil cytop...

TipRanks 5d

Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 6d

Amgen Announces CTO Retirement and Strategic Leadership Realignment

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

51%

of 37 ratings

Buy

40.5%

Hold

51.4%

Sell

8.1%

More AMGN News

Simply Wall St 6d

The Bull Case For Amgen Could Change Following Strong Q4 Beat And Upbeat 2026 Guidance

Amgen recently reported fourth-quarter 2025 results that exceeded revenue and adjusted EPS expectations, followed by guidance that projected stronger adjusted e...

TipRanks 6d

Amgen announces retirement of CTO and other executive changes

Amgen (AMGN) announced the retirement of David M. Reese, M.D., EVP and Chief Technology Officer, effective June 30. Reese joined Amgen in 2005 as a clinical dev...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.